CN116096404A - 多肽、组合物及其用于治疗或限制感染发展的用途 - Google Patents

多肽、组合物及其用于治疗或限制感染发展的用途 Download PDF

Info

Publication number
CN116096404A
CN116096404A CN202180028727.9A CN202180028727A CN116096404A CN 116096404 A CN116096404 A CN 116096404A CN 202180028727 A CN202180028727 A CN 202180028727A CN 116096404 A CN116096404 A CN 116096404A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
seq
nanoparticle
rbd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180028727.9A
Other languages
English (en)
Chinese (zh)
Inventor
N·P·金
D·维斯勒
C·沃基
A·C·沃尔斯
J·Y·王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of CN116096404A publication Critical patent/CN116096404A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180028727.9A 2020-02-14 2021-02-12 多肽、组合物及其用于治疗或限制感染发展的用途 Pending CN116096404A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062977036P 2020-02-14 2020-02-14
US62/977,036 2020-02-14
US202063046159P 2020-06-30 2020-06-30
US63/046,159 2020-06-30
US202063064235P 2020-08-11 2020-08-11
US63/064,235 2020-08-11
PCT/US2021/017799 WO2021163438A1 (en) 2020-02-14 2021-02-12 Polypeptides, compositions, and their use to treat or limit development of an infection

Publications (1)

Publication Number Publication Date
CN116096404A true CN116096404A (zh) 2023-05-09

Family

ID=74873805

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180028727.9A Pending CN116096404A (zh) 2020-02-14 2021-02-12 多肽、组合物及其用于治疗或限制感染发展的用途

Country Status (13)

Country Link
US (1) US20240277831A1 (https=)
EP (1) EP4103230A1 (https=)
JP (1) JP2023513720A (https=)
KR (1) KR20220142472A (https=)
CN (1) CN116096404A (https=)
AU (1) AU2021221139A1 (https=)
BR (1) BR112022016220A2 (https=)
CA (1) CA3167318A1 (https=)
CO (1) CO2022011467A2 (https=)
MX (1) MX2022009860A (https=)
PE (1) PE20230301A1 (https=)
PH (1) PH12022552099A1 (https=)
WO (1) WO2021163438A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
JP2023521418A (ja) 2020-04-10 2023-05-24 インビビド， インコーポレイテッド コロナウイルスｓタンパク質に特異的な化合物及びその使用
WO2022016122A2 (en) * 2020-07-17 2022-01-20 Tonix Pharmaceuticals Holding Corp. Skin-based testing for detection of cell-mediated immune responses to sars-cov-2
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
US20220324918A1 (en) * 2021-03-30 2022-10-13 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE ECTODOMAIN POLYPEPTIDES AND COMPOSITIONS AND METHODS THEREOF
WO2023034991A1 (en) * 2021-09-02 2023-03-09 Kansas State University Research Foundation Mrna vaccine formulations and methods of using the same
US20240385189A1 (en) * 2021-09-10 2024-11-21 Jacobs Technion-Cornell Institute Compositions and methods for determining humoral immune responses against seasonal coronaviruses and predicting efficiency of sars-cov-2 spike targeting, covid-19 disease severity, and providing interventions
KR102527221B1 (ko) * 2021-10-15 2023-05-02 에스케이바이오사이언스 주식회사 단백질의 정제방법
KR102621026B1 (ko) * 2021-10-15 2024-01-09 에스케이바이오사이언스(주) 단백질의 정제방법
KR102524839B1 (ko) * 2021-11-04 2023-04-25 에스케이바이오사이언스(주) 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물
US20250000968A1 (en) * 2021-11-12 2025-01-02 The United States of America, as represented by the Secretary,Department of Health and Human Service Sars-cov-2 spike fused to a hepatitis b surface antigen
WO2023122257A2 (en) * 2021-12-22 2023-06-29 La Jolla Institute For Immunology Coronavirus spike glycoprotein with improved expression and stability
CN114656571B (zh) * 2022-02-18 2024-07-16 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种四价SARS-CoV-2嵌合纳米颗粒疫苗及其制备方法与应用
US20240207389A1 (en) * 2022-04-27 2024-06-27 Northwestern University Methods for improving covid vaccine immunogenicity
WO2024014943A1 (ko) * 2022-07-12 2024-01-18 에스케이바이오사이언스 주식회사 Sars-cov-2 백신 부스터 조성물
WO2024076982A2 (en) * 2022-10-05 2024-04-11 University Of Washington Pan-sarbecovirus nanoparticle vaccines
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016639A2 (en) * 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
WO2017046801A1 (en) * 2015-09-17 2017-03-23 Ramot At Tel-Aviv University Ltd. Coronaviruses epitope-based vaccines
WO2018175560A1 (en) * 2017-03-22 2018-09-27 The Scripps Research Institute Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain
CA3095216A1 (en) * 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10248758B2 (en) * 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
CN105934441A (zh) * 2013-11-26 2016-09-07 贝勒医学院 新型sars免疫原性组合物
US9630994B2 (en) * 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
HUE073526T2 (hu) * 2017-04-04 2026-01-28 Univ Washington Önmagát összeállító fehérje nanostruktúrák, amelyek paramyxovírus és/vagy pneumovírus F fehérjéket jelenítenek meg és azok használata

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016639A2 (en) * 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
WO2017046801A1 (en) * 2015-09-17 2017-03-23 Ramot At Tel-Aviv University Ltd. Coronaviruses epitope-based vaccines
WO2018175560A1 (en) * 2017-03-22 2018-09-27 The Scripps Research Institute Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain
CA3095216A1 (en) * 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
WO2019169120A1 (en) * 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JACINTO等: "nanoparticles in the design of vaccines", COMPUTATIONAL AND STRUCTIRAL BIOTECHNOLOGY JOURNAL, 1 January 2016 (2016-01-01), pages 58 - 68 *
NISREEN M.A. OKBA等: "particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV", EMERGING MICROBES & INFECTIONS, 1 January 2020 (2020-01-01), pages 1080 - 1091 *

Also Published As

Publication number Publication date
PH12022552099A1 (en) 2024-01-29
CA3167318A1 (en) 2021-08-19
MX2022009860A (es) 2022-11-07
US20240277831A1 (en) 2024-08-22
EP4103230A1 (en) 2022-12-21
AU2021221139A1 (en) 2022-09-01
PE20230301A1 (es) 2023-02-13
KR20220142472A (ko) 2022-10-21
CO2022011467A2 (es) 2022-10-31
BR112022016220A2 (pt) 2022-10-25
JP2023513720A (ja) 2023-04-03
WO2021163438A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
CN116096404A (zh) 多肽、组合物及其用于治疗或限制感染发展的用途
US20250171500A1 (en) Conformationally stabilized rsv pre-fusion f proteins
Walls et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2
Tan et al. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
US20230109393A1 (en) Designer peptides and proteins for the detection, prevention and treatment of coronavirus disease, 2019 (covid-19)
US20200361997A1 (en) Conformationally stabilized rsv pre-fusion f proteins
CN117957016A (zh) Sars-cov-2与流感联合疫苗
CN116096733A (zh) Covid-19融合蛋白的抗原特异性免疫疗法和使用方法
EP3758747A1 (en) Self-asssembling nanostructure vaccines
EP2536425A2 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
CN108738312A (zh) Rsv f蛋白突变体
CN116096407A (zh) 重组人偏肺病毒f蛋白及其用途
KR20210018206A (ko) 항원성 호흡기 세포융합 바이러스 폴리펩타이드
KR20230107621A (ko) 메타뉴모바이러스에 대한 단백질-기반 나노입자 백신
HK40094028A (zh) 多肽、组合物及其用於治疗或限制感染发展的用途
US20250161436A1 (en) Multivalent vaccine for paramyxoviruses and uses thereof
RU2843302C1 (ru) Самособирающийся белковый комплекс 24xApofRBD, полученный слиянием апоферритина с рецептор-связывающим доменом S-белка SARS-CoV-2
US20260069679A1 (en) Coronavirus spike protein-based vaccines
WO2025026448A1 (zh) 修饰的呼吸道合胞病毒f蛋白及其用途
TW202517664A (zh) 流感神經胺酸酶四聚體
CN116964104A (zh) 免疫原性冠状病毒融合蛋白及相关方法
HK40110532A (zh) 冠状病毒和流感病毒组合物和其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40094028

Country of ref document: HK